Showing results (81-90 of 90) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
The Journal of Experimental Medicine|December 21, 2005
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillanceMasaki Terabe, Jeremy Swann, Elena Ambrosino, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 11, 2011
Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80Samuel T Haile, Jacobus J Bosch, Nnenna I Agu, et al.Haematologica|November 12, 2009
Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responsesMarvin M van Luijn, Martine E D Chamuleau, James A Thompson, et al.Transplantation|July 26, 2019
Differential Regulation of T-cell Immunity and Tolerance by Stromal Laminin Expressed in the Lymph NodeThomas Simon, Lushen Li, Chelsea Wagner, et al.Cancer Immunology, Immunotherapy : CII|September 8, 2010
Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexesMarvin M van Luijn, Martine E D Chamuleau, Maaike E Ressing, et al.Nature Communications|July 7, 2016
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standardsVincenzo Bronte, Sven Brandau, Shu-Hsia Chen, et al.Cancer Discovery|July 24, 2012
IDO is a nodal pathogenic driver of lung cancer and metastasis developmentCourtney Smith, Mee Young Chang, Katherine H Parker, et al.The Journal of Clinical Investigation|May 19, 2020
Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focusAnca Dorhoi, Leigh A Kotzé, Jay A Berzofsky, et al.Elife|December 9, 2016
Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodesAmy W Ku, Jason B Muhitch, Colin A Powers, et al.Nature Medicine|April 25, 2018
Understanding the tumor immune microenvironment (TIME) for effective therapyMikhail Binnewies, Edward W Roberts, Kelly Kersten, et al.Pageof 9